Bain Capital, LP is one of the world’s leading private investment firms with approximately $160 billion of assets under management that creates lasting impact for our investors, teams, businesses, and the communities in which we live. Since our founding in 1984, we’ve applied our insight and experience to organically expand into several asset classes including private equity, credit, public equity, venture capital and real estate. We leverage our shared platform to capture cross-asset class opportunities in strategic areas of focus. With offices on four continents, our global team aligns our interests with those of our investors for lasting impact.

Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact ir@baincapital.com.

Bain Capital Private Equity agrees to acquire Evident, formerly known as Olympus Scientific Solutions

August 29, 2022

Media Contacts

Share this page

Acquisition to support independent company’s product innovation and expansion in existing and new global markets 

TOKYO– Aug 29, 2022 –  Bain Capital Private Equity (“Bain Capital”), a leading global private investment firm today announced it has signed a definitive agreement to acquire Evident Corporation (“Evident”), a subsidiary of Olympus Corporation (“Olympus”).

Evident is a world-leading manufacturer of microscopes for life science and industrial applications, videoscopes for remote visual inspection and non-destructive test equipment. As an independent company, Evident will continue over 100 years of innovation in imaging, instrumentation and measurement solutions, underpinned by deep and broad customer relationships, best-in-class technology and differentiated capabilities in R&D and precision manufacturing.

Yuji Sugimoto, Managing Director of Bain Capital in Japan, said “We are excited to partner with Evident’s management team and help realize their ambition to grow their digital products and solutions, workflow integration and automation businesses.  We will fully commit Bain Capital’s global resources and our team’s accumulated experience to assist Evident to realize these attractive growth opportunities and to create value for all stakeholders.”

Stephen Thomas, Managing Director of Bain Capital in North America, added “Evident is at the frontier of digital optical technology in life sciences and industrial end markets, and has great potential to expand into new products, new customers and new markets as an independent company.”

Bain Capital Private Equity has deep experience supporting the growth and innovation of industrial technology companies globally, including II-VI, Kioxia, Sensata and NXP. Bain Capital’s global platform in Healthcare and Life Science has similar depth in pathology and life science instrumentation.

The investment is expected to be completed in the first quarter of 2023 subject to regulatory approvals and closing conditions.

###

About Bain Capital Private Equity

Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital Private Equity's global team of more than 250 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare, consumer/retail, financial and business services, industrials, and technology, media and telecommunications. Bain Capital has 23 offices on four continents. The firm has made primary or add-on investments in more than 1,100 companies since its inception. In addition to private equity, Bain Capital invests across multiple asset classes, including credit, public equity, venture capital and real estate, managing approximately $160 billion in total assets and leveraging the firm's shared platform to capture opportunities in strategic areas of focus. 

For more information, visit www.baincapitalprivateequity.com.